Inpatient serious illness care program for Myelodysplastic Syndromes

Phase-Based Progress Estimates
University of Rochester, Rochester, NY
Myelodysplastic Syndromes+6 More
Inpatient serious illness care program - Behavioral
All Sexes
What conditions do you have?

Study Summary

This is a pilot study to assess the preliminary efficacy of an inpatient advanced care practitioner (APP)-delivered advance care planning intervention on outcomes in older patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Eligible Conditions

  • Myelodysplastic Syndromes
  • Acute Myeloid Leukemia (AML)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Myelodysplastic Syndromes

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Up to 5 years following their participation in the study or death

12 weeks
Completion of advance directives
Year 5
End of life quality indicators

Trial Safety

Safety Progress

1 of 3

Other trials for Myelodysplastic Syndromes

Trial Design

1 Treatment Group

1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: Inpatient serious illness care program · No Placebo Group · N/A

Experimental Group · 1 Intervention: Inpatient serious illness care program · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years following their participation in the study or death

Trial Background

Prof. Kah Poh Loh, Assistant Professor
Principal Investigator
University of Rochester
Closest Location: University of Rochester · Rochester, NY
Photo of University of Rochester  1Photo of University of Rochester  2Photo of University of Rochester  3
2013First Recorded Clinical Trial
10 TrialsResearching Myelodysplastic Syndromes
554 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are being managed in the inpatient setting.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.